Strata Skin Sciences (NASDAQ: SSKN) issues Q2 2025 results release

Rhea-AI Filing Summary

Strata Skin Sciences, Inc. filed a current report to let investors know it has issued a press release covering its results of operations for the second fiscal quarter ended June 30, 2025. The company furnished the full text of this press release as Exhibit 99.1 to the report, using Items 2.02 and 7.01 to share the information. The company states that this exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings unless specifically referenced.

false000105151400010515142025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 13, 2025

STRATA SKIN SCIENCES, INC.

(Exact Name of Registrant Specified in Charter)

Delaware	000-51481	13-3986004
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania		19044
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code:   215-619-3200

 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the second fiscal quarter ended June 30, 2025. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 7.01. Regulation FD Disclosure.

On August 13, 2025, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the second fiscal quarter ended June 30, 2025. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

	99.1	Press Release dated August 13, 2025 issued by STRATA Skin Sciences, Inc.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	STRATA SKIN SCIENCES, INC.
Date: August 13, 2025	By:	/s/ John Gillings
		Chief Accounting Officer

-3-

FAQ

What did STRATA Skin Sciences (SSKN) disclose in this 8-K filing?

The company disclosed that it issued a press release announcing its results of operations for the second fiscal quarter ended June 30, 2025, and furnished the release as Exhibit 99.1.

Which period do the STRATA Skin Sciences (SSKN) results relate to?

The results discussed in the press release relate to the company’s second fiscal quarter ended June 30, 2025.

Where can investors find the STRATA Skin Sciences Q2 2025 results details?

Investors can find the detailed results of operations in the press release that is furnished as Exhibit 99.1 to this report.

Is the STRATA Skin Sciences Q2 2025 press release considered filed with the SEC?

No. The company states that the information under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Which exhibits are included with this STRATA Skin Sciences (SSKN) report?

The report includes Exhibit 99.1, the press release dated August 13, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the STRATA Skin Sciences 8-K related to the Q2 2025 press release?

The report was signed on behalf of STRATA Skin Sciences, Inc. by John Gillings, Chief Accounting Officer.